Pentoxifylline for diabetic kidney disease

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 2, 2012, Pages

  Shan, Dan ^a   Wu, Hong Mei ^a   Yuan, Qi Yuan ^b   Li, Jun ^a   Zhou, Rong Le ^c   Liu, Guan J ^a  

^a SICHUAN UNIVERSITY   (China)

^b No 4 People's Hospital of Chengdu   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; CLONIDINE; METHYLDOPA; PENTOXIFYLLINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ALBUMINURIA; CAUSE OF DEATH; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPEPSIA; END STAGE RENAL DISEASE; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEADACHE; HEART ARRHYTHMIA; HOT FLUSH; HUMAN; HYPOTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT WITHDRAWAL; VOMITING; BLOOD; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALBUMINURIA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIABETIC NEPHROPATHIES; HUMANS; PENTOXIFYLLINE; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861314066     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006800.pub2     Document Type: Review

References (97)

1. Aminorroaya A, Janghorbani M, Rezvanian H, Aminian T, Gharavi M, Amini M. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron 2005;99(3):c73-7. [MEDLINE: 15665549].
2. Gan N, Kong YZ, Liu SF. Clinical observation of pentoxifylline in reducing proteinuria in patients with diabetic nephropathy. Shiyong Yixue Zazhi [Journal of Practical Medicine] 2003;19(12):1365-6.
3. Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR, Garcia-Bulnes G, Salas-Ramirez M, Amato D. Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clinical Nephrology 1995;43(2):116-21. [MEDLINE: 7736673].
4. Harmankaya O, Erimez D, Altuntas Y, Basturk T, Obek A, Unsal A. Combination of pentoxifylline with angiotensin converting enzyme inhibitors (ACEi) produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients [abstract]. Nephrology Dialysis Transplantation 2002;17(Suppl 1):25-6.
5. Harmankaya O, Seber S, Yilmaz M. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Renal Failure 2003;25(3):465-70. [MEDLINE: 12803510].
6. Leyva-Jimenez R, Rodriguez-Orozco AR, Ortega-Pierres LE, Ramirez-Enriquez J, Gomez-Garcia A, Varez-Aguilar C. Effect of pentoxifylline on the evolution of diabetic nephropathy. Medicina Clinica 2009;132(20):772-8. [EMBASE: 2009266322].
7. Navarro JF, Mora C. Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy. Diabetes Care 1999;22(6):1006-8. [MEDLINE: 10372263].
8. Navarro JF, Mora C, Gallego E, Chahin J, Macia M, Mendez M, et al.Pentoxifylline (PTF) reduces proteinuria and tumor necrosis factor-alpha (TNFa) in diabetic patients with advanced renal failure [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):120A.
9. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Macia M, et al.Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. American Journal of Kidney Diseases 1999;33(3):458-63. [MEDLINE: 10070909].
10. Navarro JF, Mora C, Muros M, Maca M, Garca J. Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. American Journal of Kidney Diseases 2003;42(2):264-70. [MEDLINE: 12900807].
11. Navarro J, Mora C, Henriquez F, Muros M, Macia M, Garcia J. Additive antiproteinuric effect of pentoxifylline in diabetic nephropathy [abstract]. Journal of the American Society of Nephrology 2005;16:58A.
12. Navarro J, Mora C, Henriquez F, Muros M, Rodriguez A, del Castillo N, et al.Additive antiproteinuric effect of pentoxifylline in type 2 diabetic patients under angiotensin II receptor blockade [abstract]. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v239.
13. Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. Journal of the American Society of Nephrology 2005;16(7):2119-26. [MEDLINE: 15917336].
14. Pang JGH, Zhang XP, Zhi ZJ. Effect of pentoxifylline in the treatment of early diabetic nephropathy. Linchuang Huicui [Clinical Focus] 2003;18(20):1185.
15. Pantoja R, Woronik V, Barros R. Effects of pentoxifylline in diabetic nephropathy [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):104.
16. Rodriguez-Moran M, Guerrero-Romero F. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients - a randomized, equivalent trial. Clinical Nephrology 2005;64(2):91-7. [MEDLINE: 16114784].
17. Rodriguez-Moran M, Gonzalez-Gonzalez G, Bermudez-Barba MV, Medina de la Garza CE, Tamez-Perez HE, Martinez-Martinez FJ, et al.Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial. Clinical Nephrology 2006;66(1):3-10. [MEDLINE: 16878429].
18. Solerte SB, Fioravanti M, Bozzetti A, Schifino N, Patti AL, Fedele P, et al.Pentoxifylline, albumin excretion rate and proteinuria in type I and type II diabetic patients with microproteinuria. Results of a short-term randomized study. Acta Diabetologica Latina 1986;23(2):171-7. [MEDLINE: 3751450].
19. Solerte SB, Fioravanti M, Patti AL, Schifino N, Zanoletti MG, Inglese V, et al.Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy. Acta Diabetologica Latina 1987;24(3):229-39. [MEDLINE: 3687315].
20. Sui CH, Sheng HG, Yang YG. Effect of pentoxifylline on diabetic nephropathy. Shanghai Yufang Yixue [Shanghai Journal of Preventive Medicine] 1999;11(10):460-2.
21. Zang QL, Su RS. The effect of pentoxifylline in the treatment of early diabetic nephropathy. TianJin Medicine 1999;27(4):229-31.
22. Zhang Z, Yu DM, Zhao W, Li SY, Guo LY, Wang H. Effect of pentoxifylline in the treatment of early diabetic nephropathy in the elderly. Zhongguo ZhongXiyi Jiehe Jijiu Zazhi [Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care] 2001;8(4):213-5.
23. Cen JQ. Pentoxifylline in the treatment of diabetic nephropathy. Chinese Journal of Current Practical Medicine 2005;4(7):57-8.
24. Chua AT, Yu RMH. Effect of pentoxifylline on the course of diabetic nephropathy [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong. 1995:111.
25. Demir E, Paydas S, Balal M, Erken U. Effects of pentoxifylline on the cytokines that may play a role in rejection and resistive index in renal transplant recipients [abstract]. Transplant International 2007;20(Suppl 2):183.
26. Diao JH. Pentoxifylline in the treatment of diabetic nephropathy. Shanxi Yiyao Zazhi [Shanxi Medical Journal] 2003;32(12):1144-5.
27. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?. Journal of Nephrology 2007;20(4):410-6. [MEDLINE: 17879206].
28. Garg SK, Chase HP, Jackson WE, Harris S, Carmain JA, Hansen MH, et al.Renal and retinal changes after treatment with ramipril and pentoxifylline in subjects with IDDM. Annals of Ophthalmology-Glaucoma 1998;30(1):33-7. [EMBASE: 1998093196].
29. Gonzalez-Espinoza L, Medina M, Gomez-Navarro B, Cueto-Manzano A. Pentoxifylline decreases C-reactive protein in hemodialysis: a randomized, double-blinded, controlled clinical trial [abstract]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):4A.
30. Laczy B, Cseh J, Mohas M, Marko L, Tamasko M, Koszegi T, et al.Effects of pentoxifylline and pentosan polysulphate combination therapy on diabetic neuropathy in type 2 diabetes mellitus. Acta Diabetologica 2009;46(2):105-11. [MEDLINE: 18839054].
31. Lin S, Chen Y, Chiang W, Wu K, Tsai T. Add-on pentoxifylline attenuated residual proteinuria in patients of moderate to advanced chronic kidney disease receiving maximized losartan treatment [abstract]. Journal of the American Society of Nephrology 2006;17(Abstracts):56A.
32. Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. American Journal of Kidney Diseases 2008;52(3):464-74. [MEDLINE: 18617301].
33. Maiti R, Agrawal NK, Dash D, Pandey BL. Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. Vascular Pharmacology 2007;47(2-3):118-24. [MEDLINE: 17613279].
34. Mooraki A, Jenabi A, Jabbari M, Sabet Z, Golestanpour A, Yosefizadeh A, et al.Remarkable effects of pentoxifylline on microalbuminuria and serum CRP in diabetic patients [abstract]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv83.
35. Navarro JF, Macia M, Mora C, Garcia-Nieto VG, Chahin J, Gallego E, et al.Effects of pentoxifylline on hemotologic status in anemic patients with advanced renal failure [abstract]. Journal of the American Society of Nephrology 1996;7(9):1493.
36. Navarro JF, Mora C, Garcia J, Rivero A, Macia M, Gallego E, et al.Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scandinavian Journal of Urology & Nephrology 1999;33(2):121-5. [MEDLINE: 10360454].
37. Paap CM, Simpson KS, Horton MW, Schaefer KL, Lassman HB, Sack MR. Multiple-dose pharmacokinetics of pentoxifylline and its metabolites during renal insufficiency. Annals of Pharmacotherapy 1996;30(7-8):724-9. [MEDLINE: 8826548].
38. Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. American Journal of Kidney Diseases 2009;53(4):606-16. [MEDLINE: 19216016].
39. Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Pentoxifylline in patients with progressive chronic kidney disease: a pilot, double-blind, randomized, placebo-controlled trial [abstract]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):46A.
40. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20(7):1183-97. [MEDLINE: 9203460].
41. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, et al.Nephropathy in diabetes. Diabetes Care 2004;27 Suppl 1:S79-83. [MEDLINE: 14693934].
42. Aminorroaya A, Janghorbani M, Rezvanian H, Aminian T, Gharavi M, Amini M. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron 2005;99(3):c73-7. [MEDLINE: 15665549].
43. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, et al.Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2003;26(7):2150-5. [MEDLINE: 12832328].
44. Chantrel F, Enache I, Bouiller M, Kolb I, Kunz K, Petitjean P, et al.Abysmal prognosis of patients with type 2 diabetes entering dialysis. Nephrology Dialysis Transplantation 1999;14(1):129-36. [MEDLINE: 10052492].
45. Chen J, Gall M, Yokoyama H, Jensen J, Deckert M, Parving HH. Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy. Diabetes Care 1996;19(2):130-4. [MEDLINE: 8718432].
46. Chen YM, Chien CT, Hu-Tsai MI, Wu KD, Tsai CC, Wu MS, et al.Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney International 1999;56(3):932-43. [MEDLINE: 10469361].
47. Chen YM, Ng YY, Lin SL, Chiang WC, Lan HY, Tsai TJ. Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. Nephrology Dialysis Transplantation 2004;19(5):1106-15. [MEDLINE: 14993492].
48. Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D, et al.Excerpts from the United States Renal Data System 2004 Annual Data Report: Atlas of end-stage renal disease in the United States. American Journal of Kidney Diseases 2003;42(1 Suppl 1):A5-7. [MEDLINE: 15640975].
49. de Zeeuw D. Albuminuria: a target for treatment of type 2 diabetic nephropathy. Seminars in Nephrology 2007;27(2):172-81. [MEDLINE: 17418686].
50. Eijkelkamp WB, Zhang Z, Remuzzi G. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Journal of the American Society of Nephrology 2007;18(5):1540-6. [MEDLINE: 17409317].
51. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney International 2000;58(4):1703-10. [MEDLINE: 11012904].
52. Guerrero-Romero F, Rodrguez-Mora M, Paniagua-Sierra J, Garca-Bulnes G, Salas-Ramrez M, Amato D. Pentoxifylline reduces proteinuria in insulin-dependent and non insulin dependent diabetic patients. Clinical Nephrology 1995;43(2):116-21. [MEDLINE: 7736673].
53. Han KH, Han SY, Kim HS, Kang YS, Cha DR. Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy. Inflammation 2010;33(3):137-43. [MEDLINE: 19921414].
54. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120].
55. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
56. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. New England Journal of Medicine 2001;344(21):1594-602. [MEDLINE: 11372012].
57. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313(7048):36-9. [MEDLINE: 8664772].
58. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. American Journal of Kidney Diseases 2004;43(5 Suppl 1):S1-290.
59. Kidney Disease Outcomes Quality Initiative (K/DOQI). KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. American Journal of Kidney Diseases 2007;49(2 Suppl 2):S12-154. [MEDLINE: 17276798].
60. Kjaergard LL, Villumsen J, Gluud C. Quality of randomised clinical trials affects estimates of intervention efficacy. Seventh International Cochrane Colloquium; 1999 Oct 5-9; Rome (Italy). 1999:57.
61. Lin SL, Chen YM, Chien CT, Chiang WC, Tsai CC, Tsai TJ. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. Journal of the American Society of Nephrology 2002;13(12):2916-29. [MEDLINE: 12444210].
62. McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: A meta-analysis. American Journal of Kidney Diseases 2008;52(3):454-63. [MEDLINE: 18433957].
63. McCullough PA, Bakris GL, Owen WF Jr, Klassen PS, Califf RM. Slowing the progression of diabetic nephropathy and its cardiovascular consequences. American Heart Journal 2004;148(2):243-51. [MEDLINE: 15308993].
64. Middleton RJ, Foley RN, Hegarty J, Cheung CM, McElduff P, Gibson JM, et al.The unrecognized prevalence of chronic kidney disease in diabetes. Nephrology Dialysis Transplantation 2006;21(1):88-92. [MEDLINE: 16221715].
65. Mogensen CE. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes 1997;46 Suppl 2:S104-11. [MEDLINE: 9285510].
66. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13. [MEDLINE: 9746022].
67. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al.HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007784].
68. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Maca M, et al.Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. American Journal of Kidney Diseases 1999;33(3):458-63. [MEDLINE: 10070909].
69. Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. American Journal of Kidney Diseases 2003;42(1):53-61. [MEDLINE: 12830456].
70. Navarro J. Diabetic nephropathy: A matter of inflammation?. Nefrologia 2003;23(5):381-9. [MEDLINE: 14658163].
71. Navarro J, Mora C, Muros M, Maca M, Garca J. Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. American Journal of Kidney Diseases 2003;42(2):264-70. [MEDLINE: 12900807].
72. Navaroo JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. Journal of the American Society of Nephrology 2005;16(7):2119-26. [MEDLINE: 15917336].
73. Navarro JF, Milena FJ, Mora C, Leon C, Garcia J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. American Journal of Nephrology 2006;26(6):562-70. [MEDLINE: 17167242].
74. Navarro-Gonzalez JF, Mora-Fernandez C. The role of Inflammatory cytokines in diabetic nephropathy. Journal of the American Society of Nephrology 2008;19(3):433-42. [MEDLINE: 18256353].
75. Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlof B, Devereux RB, et al.Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. Journal of Hypertension 2006;24(4):755-81. [MEDLINE: 16531808].
76. Rabbani N, Alam SS, Riaz S, Larkin JR, Akhtar MW, Shafi T, et al.High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia 2009;52(2):208-12. [MEDLINE: 19057893].
77. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. American Journal of Kidney Diseases 1999;34(5):795-808. [MEDLINE: 10561134].
78. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. New England Journal of Medicine 1999;341(15):1127-33. [MEDLINE: 10511612].
79. Ritz E. Diabetic nephropathy. Saudi Journal of Kidney Diseases & Transplantation 2006;17(4):481-90. [MEDLINE: 17186681].
80. Rivero A, Mora C, Muros M, Garcia J, Herrera H, Navarro-Gonzalez JF. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clinical Science 2009;116(6):479-92. [MEDLINE: 19200057].
81. Robertson LM, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD002181.pub2].
82. Rochon PA, Binns MA, Litner JA, Litner GM, Fischbach MS, Eisenberg D. Are randomized control trial outcomes influenced by the inclusion of a placebo group?: A systematic review of nonsteroidal antiinflammatory drug trials for arthritis treatment. Journal of Clinical Epidemiology 1999;52(2):113-22. [MEDLINE: 10201651].
83. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. [MEDLINE: 7823387].
84. Segal R, Dayan M, Zinger H, Mozes E. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxifylline. Lupus 2001;10(1):23-31. [MEDLINE: 11243506].
85. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD006257].
86. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD004136.pub2].
87. Tonolo G, Velussi M, Brocco E, Abaterusso C, Carraro A, Morgia G, et al.Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney International 2006;70(1):177-86. [MEDLINE: 16710349].
88. Tripathy K, Prakash J, Appaiha D, Srivastava PK. Pentoxifylline in management of proteinuria in diabetic nephropathy. Nephron 1993;64(4):641-2. [MEDLINE: 8366994].
89. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA 1994;271(20):1609-14. [MEDLINE: 7880221].
90. National Institute of Diabetes and Digestive and Kidney Diseases. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. http://www.usrds.org/atlas09.aspx. Bethesda, MD, (accessed 20 December 2011).
91. National Institute of Diabetes and Digestive and Kidney Diseases. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. http://www.usrds.org/atlas.aspx (accessed 10 January 2012).
92. Ustundag A, Tugrul A, Ustundag S, Sut N, Demirkan B. The effects of spironolactone on nephron function in patients with diabetic nephropathy. Renal Failure 2008;30(10):982-91. [MEDLINE: 19016150].
93. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287(14):1840-7. [MEDLINE: 11939870].
94. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987;34(1):50-97. [MEDLINE: 3308412].
95. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf (accessed 20 December 2011).
96. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5. [MEDLINE: 18316340].
97. Wu HM, Yuan QY, Zhou RL, Li J, Liu GJ. Pentoxifylline for diabetic kidney disease. Cochrane Database of Systematic Reviews 4, Issue 2007. [DOI: 10.1002/14651858.CD006800].